You just read:

CARsgen Announces Investigational CAR-T Therapy CT053 Granted RMAT Designation by the U.S. FDA for R/R Multiple Myeloma

News provided by

CARsgen Therapeutics Co. Ltd.

Oct 28, 2019, 06:00 ET